White Papers / Tech Papers
CRYSTALOMICS® FORMULATION TECHNOLOGY
Over the past decade, protein-based therapeutics have emerged as a key driver of growth in the pharmaceutical industry. R&D pipelines have filled with biologics and monoclonal antibodies have become the best-selling drugs around the world. Despite the success of this segment, the size and complexity of protein molecules create specific challenges when developing these types
To help clients overcome formulation challenges, Althea® offers access to our proprietary Crystalomics® Formulation Technology. The technology produces highly concentrated formulations with low viscosity, enabling low volume administration and increased stability. Crystalline suspensions offer alternative routes of delivery and the opportunity to extend the patent life of high value biologics.